1. Home
  2. LEGN vs EPAM Comparison

LEGN vs EPAM Comparison

Compare LEGN & EPAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • EPAM
  • Stock Information
  • Founded
  • LEGN 2014
  • EPAM 1993
  • Country
  • LEGN United States
  • EPAM United States
  • Employees
  • LEGN N/A
  • EPAM N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • EPAM EDP Services
  • Sector
  • LEGN Health Care
  • EPAM Technology
  • Exchange
  • LEGN Nasdaq
  • EPAM Nasdaq
  • Market Cap
  • LEGN 7.0B
  • EPAM 8.2B
  • IPO Year
  • LEGN 2020
  • EPAM 2012
  • Fundamental
  • Price
  • LEGN $28.91
  • EPAM $175.76
  • Analyst Decision
  • LEGN Strong Buy
  • EPAM Buy
  • Analyst Count
  • LEGN 13
  • EPAM 16
  • Target Price
  • LEGN $75.67
  • EPAM $229.00
  • AVG Volume (30 Days)
  • LEGN 1.7M
  • EPAM 831.5K
  • Earning Date
  • LEGN 05-13-2025
  • EPAM 05-08-2025
  • Dividend Yield
  • LEGN N/A
  • EPAM N/A
  • EPS Growth
  • LEGN N/A
  • EPAM N/A
  • EPS
  • LEGN N/A
  • EPAM 7.15
  • Revenue
  • LEGN $728,303,000.00
  • EPAM $4,864,167,000.00
  • Revenue This Year
  • LEGN $64.21
  • EPAM $15.10
  • Revenue Next Year
  • LEGN $53.69
  • EPAM $7.61
  • P/E Ratio
  • LEGN N/A
  • EPAM $24.60
  • Revenue Growth
  • LEGN 112.46
  • EPAM 4.72
  • 52 Week Low
  • LEGN $27.34
  • EPAM $138.15
  • 52 Week High
  • LEGN $60.87
  • EPAM $269.00
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 39.95
  • EPAM 52.55
  • Support Level
  • LEGN $28.14
  • EPAM $177.00
  • Resistance Level
  • LEGN $31.12
  • EPAM $187.56
  • Average True Range (ATR)
  • LEGN 1.87
  • EPAM 5.36
  • MACD
  • LEGN -0.16
  • EPAM 0.60
  • Stochastic Oscillator
  • LEGN 25.95
  • EPAM 58.52

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About EPAM EPAM Systems Inc.

EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.

Share on Social Networks: